What Enbrel needs to do after its patent win
A US patent victory could give Amgen’s Enbrel another eight years’ patent exclusivity, but is the enthusiasm justified?
Lexicon and Sanofi fall out over semantics
Citing study failure, Sanofi terminates its tie-up with Lexicon covering Zynquista; not so fast, says Lexicon, and claims breach of contract.
Aegerion’s poisoned chalice gives Amryt some distraction therapy
Three years after being merged with QLT the Aegerion business is to be sold out of bankruptcy protection.
Price fixing case caps a terrible week for generics
Shares in generics firms tumble in the wake of a huge lawsuit in the US alleging industry-wide price fixing, signalling many more years of pain for this sector.
Upcoming events – a legal verdict for Enbrel and a clinical one for Cymabay
Amgen awaits a make-or-break US verdict on its best-selling drug, while Cymabay looks for evidence that it could become a Nash contender.
For Celgene the unthinkable suddenly looks less improbable
Celgene stock falls 9%, suggesting that an activist campaign to derail its takeover by Bristol-Myers Squibb is reaching critical mass.
Boston and Edwards make a smart judgement
The immensely complex and long-running intertwined litigation between the two medtechs has been brought to an end.
Medtech news over the Christmas period
Vantage’s roundup of medtech news you might have missed includes Boston Scientific hitting its 11th biz dev deal of the year.
The FDA’s proposed changes to device regulation are thin on detail
The FDA has made a lot of noise about its plans to make medical devices safer. But these plans are somewhat amorphous; any meaningful steps would likely require…
